Status:
COMPLETED
Pentoxifylline Role Against Chemotherapy-induced Neuropathy
Lead Sponsor:
Beni-Suef University
Conditions:
Chemotherapy-induced Peripheral Neuropathy
Eligibility:
FEMALE
18-80 years
Phase:
NA
Brief Summary
Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating side effect of neurotoxic cancer treatment. Estimated to occur in up to 80% of paclitaxel-treated patients with breast ca...
Eligibility Criteria
Inclusion
- Adult patients\> 18 years old.
- Female patients Breast cancer patients who received paclitaxel-based regimen for 12 weeks.
- Eastern Cooperative Oncology Group (ECOG) performance ≤ 2-Adequate bone marrow function.
- Adequate liver and kidney function.
Exclusion
- Children less than 18 years old.
- Evidence of physical diseases or major surgery.
- Patientswith a history of chronic diseases including; renal, hepatic, gastrointestinal, respiratory, hematological, and metabolic or other diseases.
- Patients with preexisting clinical neuropathy.
- Patients with diabetes mellitus.
- Metastatic breast cancer.
- Patients receiving medications that ameliorate neuropathy like; antidepressants, anticonvulsants, opioids, adjuvant or topical analgesics.
- Patients treated with medications that increase the risk of neuropathy.
- Hypersensitivity to pentoxifylline or xanthine derivatives.
- Patients retinal bleeding or active peptic ulcer.
- Patients at high risk for bleeding or taking medications that increase risk of bleeding.
Key Trial Info
Start Date :
July 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2024
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT06562998
Start Date
July 1 2022
End Date
August 1 2024
Last Update
August 20 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital
Banī Suwayf, Beni Suweif Governorate, Egypt, 13556